June 16th, 2011
FDA Says Pioglitazone Use Is Linked to Bladder Cancer
Larry Husten, PHD
The FDA has issued a safety announcement stating that the use of pioglitazone (Actos) for more than 1 year may be associated with increased risk for bladder cancer. The FDA announcement follows last week’s suspension of the drug in France and Germany by regulatory authorities in those countries. The FDA said that pioglitazone should not be […]
June 9th, 2011
Pioglitazone (Actos) Suspended in France Over Cancer Concerns
Larry Husten, PHD
Sales of the popular diabetes drug pioglitazone (Actos, Takeda) have been suspended in France after a study carried out by the French health insurance fund (CNAM) found that it may increase the risk of bladder cancer. The French regulatory agency (AFSSAPS) said that new prescriptions for drugs containing pioglitazone may no longer be written, but […]
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?